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Antifungal Prophylaxis in Severely Neutropenic 
Patients: How Much Fluconazole is Necessary? 
Christian E n  Delden', Daniel l? Lew', Bernard Chapuis2, 
Peter Rohner' and Bernard Hirschel' 
Objectives: To evaluate the efficacy of low dose fluconazole treatment for the prevention of yeast colonization and 
infection in severely neutropenic patients. 
Methods: An open randomized trial, comparing fluconazole (I00 mg per day) with nystatin (800,000 IU per day), in a 
University Hospital setting. 
Results: Antifungal prophylaxis was given during the period of neutropenia, defined as less than 500 
polymorphonuclear cells (PMN)/mm3). Thirty-six patients were randomly assigned to fluconazole and 33 to nystatin 
treatment groups. New oropharyngeal colonizations were significantly reduced by fluconazole (P=0.005), and 
oropharyngeal infections occurred less frequently in the fluconazole group (3% versus 16%. P=0.07). Stool colonization 
was identical between both groups. Systemic fungal infections were rare; one fluconazole patient had pulmonary 
aspergillosis and one nystatin patient developped Candida pseudotropicalis fungemia. Empiric amphotericin B was 
given with the same frequency in both groups. No side effects were associated with fluconazole. However, the 
administration of nystatin became impossible for three patients because of vomiting and lack of compliance. 
Conclusions: Fluconazole (100 mg per day) is more effective than nystatin for the prevention of oropharyngeal yeast 
colonization. Comparison with results in the literature suggests that a 100-mg dose of fluconazole has similar effects to 
200 or 400 mg per day. 
Key Words: Fluconazole, nystatin, neutropenia, prophylaxis, candida, colonization, infection, amphotericin B. 
Extreme and prolonged neutropenia following chemo- 
therapy is a major risk factor in exposing patients to 
fungal infections. Mortality associated with dissemi- 
nated fungal infections is high (1, 2) and treatment with 
parenteral amphotericin B is complicated by major, 
mainly renal, toxicity (3). Up to 75% of patients 
remaining neutropenic over a prolonged period of 
time will receive empiric anti-fungal therapy with 
amphotericin B because of unexplained fever and 
suspected systemic fungal infection (4, 5 ) .  Yeasts are 
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among the most common fungal pathogens in this 
patient population (6). The human gastrointestinal tract 
is a major reservoir for Candida species (7), and 
colonization of the digestive tract with Candida species 
has been associated with fungemia (8). This justifies 
primary prevention measures against yeast colonization 
and infections in patients with anticipated prolonged 
neutropenia (6,9). Prophylactic regimens using nystatin, 
clotrimazole, and ketoconazole have given inconsistent 
results (6, 10) and intravenous administration of ampho- 
tericin B (8, 11, 12) and miconazole (13) has been 
limited by toxicity and lack of efficacy. Fluconazole is 
effective in the treatment of oropharyngeal candidiasis 
and crytococcal meningitis in AIDS patients (14-16), 
in chronic disseminated candidiasis in leukemic patients 
(17-19) and in surgical non-neutropenic patients with 
candidemia (20). It is highly active against most yeasts, 
except C. krtrsei and T glabrata. Its pharmacokinetic 
profile is favorable with an excellent gastrointestinal 
absorption independent of gastric acid, a long serum 
half-life, good penetration into the cerebrospinal fluid, 
and 90% renal elimination (21). This open randomized 
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study compares fluco-nazole (100 mg/day) with the 
standard prophylactic regimen previously in use in our 
institution (nystatin 800,000 IU/day) in all patients 
hospitalized for a hematologic malignancy and who are 
expected to become extremely neutropenic (less than 
500 PMN/mm3) for at least seven consecutive days. 
The study was initially designed to determine 
whether fluconazole at  a dosage of 100 mg/day (a) 
decreases yeast colonization, (b) decreases superficial 
and systemic yeast infections, and (c) can allow one to 
reduce the empiric administration of amphotericin B. 
During the study period, two large trials were published 
showing no reduction in the use of empiric anti- 
fungal therapy even at doses of fluconazole up to 400 
mg/day (4, 5), and systemic fungal infections were no 
less frequent in leukemic patients even at such a high 
dose (5). We, therefore, stopped the study prematurely. 
Methods 
Patients 
Patients were eligible for the study if they were 
expected to become neutropenic (defined as less than 
500 polymorphonuclear cells per mm3) for at  least 
seven consecutive days, were able to swallow a liquid 
solution, were at  least 14 years of age, and had given 
informed consent approved by the local ethical review 
committee. A base line negative pregnancy test was 
required for all women of child-bearing age. Patients 
were excluded if they had been treated with antifungals 
(except for topical treatment of superficial mycoses 
of the vagina or skin) during the week preceding 
the study, had an invasive fungal infection requiring 
systemic treatment, were known to be allergic to azole 
or polyene derivatives, or had abnormal liver test results 
(aspartate transaminase (AST), alanine transferase (ALT) 
or alkaline phosphatase) with more than ten times the 
normal reference value. 
General prophylactic measures 
All patients received preventive bacterial intestinal 
decontamination based on an association of oral 
polymyxine, neomycine and vancomycin. Norflo- 
xacine was added if gram-negative rods persisted in 
the stool surveillance cultures. Patients undergoing 
bone marrow transplantation received co-trimoxazole 
to prevent Pneumocystis carinii pneumonia and prophy- 
lactic acyclovir in the case of a previous history of 
zoster. 
Study drugs 
Eligible patients were randomly assigned to receive 
either fluconazole or nystatin in a non-blind trial. 
Prevention was started either on the day chemotherapy 
was initiated or, if the patients were already neutropenic 
(<500 PMN/mm3), immediately upon admission to 
hospital. Fluconazole (100 mg) was given once a day as 
a capsule or as an intravenous infusion over 30 minutes 
if the patients became unable to swallow capsules. The 
daily dosage of fluconazole was adjusted to renal 
function. Nystatin was given as a solution to gargle and 
swallow, 200,000 IU four times per day. 
The study drug was continued throughout chemo- 
therapy and neutropenia, and was stopped when the 
absolute neutrophil count was above 500 cells per mm3. 
Administration of the study drug was discontinued 
in the case of oropharyngeal candidiasis or proven 
invasive fungal disease, fever of at  least five days in spite 
of broad spectrum antibiotic therapy, clinical suspicion 
of invasive fungal disease requiring empiric intravenous 
amphotericin B administration, major adverse effects 
attributed to the study drug or increase in liver function 
test results to more than five times the upper normal 
limit. Patients who developed a superficial cutaneous 
fungal infection were given topical econazole without 
withdrawal from the study. 
Fever was defined as a rectal temperature >38"C. 
In case of fever without obvious cause, piperacillin 
and gentamicin were initially given. If fever persisted 
after 72 hours, vancomycin was added. According to 
generally accepted guidelines, empiric amphotericin B 
therapy was initiated after a further 48 hours of 
persisting fever of unknown origin (22-24). 
Surveillance 
All patients were hospitalized and examined daily for 
clinical signs and symptoms, adverse effects, or presence 
of fungal infection. Complete blood count, liver 
function tests (AST, ALT, alkaline phosphatase, lactate 
deshydrogenase), blood urea nitrogen levels, serum 
creatinine and electrolyte levels were obtained at 
least three times weekly, until the end of the study. 
Fungal surveillance cultures were obtained weekly 
from the oropharynx, stools and blood. Cultures from 
other sites were performed if necessary. Cultures were 
scored semi-quantitatively (using the isolator blood 
culture system); for blood, stool and oropharyngeal 
specimens: +: 5-10 colonies, ++: 10-15 colonies, 
and +++: >15 colonies. 
Definition of fungal colonization and infection 
Fungal colonization was defined as one positive culture 
of more than ten colonies or at  least two consecutive 
positive cultures of less than ten colonies in the 
absence of any symptoms or signs of infection. Fungal 
infections were divided into superficial and invasive 
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infections. Superficial infections were defined as positive 
surveillance cultures with the presence of clinical 
symptoms and signs of local infection (ulceration, 
plaques, exudate, inflammation) in the absence of other 
pathogens. Invasive infections were defined as the 
presence of fungus in cultures obtained from blood, or 
from a deep tissue biopsy (pulmonary tissue, deep skin, 
muscle, or other tissues) in association with clinical 
symptoms or signs of fungal infection. 
Statistical analysis 
This study was initially designed to see if the einpiric 
administration of amphotericin B could be reduced in 
our patient population from 33% (the average % at 
our institution for the two previous years) to 10% 
(the initially hoped for reduction with fluconazole). 
It was calculated that the trial would need to include 
57 patients in each group in order to be statistically 
significant. However, the study was stopped pre- 
maturely after 37 patients had been enrolled in each 
group, because the results of two larger studies, with 
more than 500 patients, using 400 mg fluconazole 
showed that the frequency of amphotericin B use 
was not changed substantially by fluconazole treat- 
ment (4, 5). All statistical analysis were performed as 
two-tailed tests. Differences between groups were 
considered statistically significant if P was less than 0.05. 
The Fisher exact test was used to compare differences 
in pro-portions, and the equality distributions were 
compared by the Mann-Whitney test. Time to events 
was obtained using Kaplan-Meier estimates of survival 
distribution and comparisons were made using the log 
rank test. 
Results 
Patients 
Seventy-four patients were enrolled in the study, 37 in 
each group. Three patients were excluded because they 
never had less than 500 PMN/mm', and two patients 
Table 1 Patient Characteristics and Clinical Efficacv. 
~ ~~ 
Fluconazole Nystatin 
Patient characteristics 
Age (years) 
Male 
Bone marrow transplantation 
Underlying diseases 
Leukemia 
Lymphoma 
Solid tumors 
500 PMN/mm' 
Mean number of days below 
Mean number of days below 
100 PMN/mmS 
n=36 
44 (19 to 77) 
18 (50%) 
15 (42%) 
28 (781%) 
7 (19%) 
1 (3%)) 
17.7 (2 to 43) 
11.1 (0 to 39) 
Number of patients with less 
than 100 PMN/mmS 35 (97%) 
Clinical eficary n=36 
Empiric amphotericin B therapy 
Median time interval before 
Clinical success 20 (56%) 
14 (39%) 
initiation ofamphotericin B 24 days 
Documented hngal infections 4 (1 1%) 
Invasive fungal disease 1 (3%) 
Superficial fungal disease 3 (8%) 
Oropharyngeal infections 1 (3%4* 
Cutaneous infections 2 (6%) 
n=33 
41 (19 to 75)  
19 (58%) 
10 (30%) 
29 (88%)) 
0 
4 (12%) 
16.2 (4 to 32) 
8.4 ((0 to 25) 
28 (85%) 
n=3 1 
14 (45%) 
11 (36%)) 
21 days 
8 (26%) 
1 (3%) 
7 (23%)) 
5 (16%)* 
2 (6%) 
None of the differences were statistically significant (P>0.1), except: 
*P=0.07. 
Table 2 Fungal Colonization. 
Oropharynx 
Fluconazole Nvstatin 
Stools 
Fluconazole Nvstatin 
Patients 
Initially colonized 
Remaining non-colonized 
Remaining colonized 
Becoming newly colonized 
With elimination of initial colonization 
Oganisms 
Caridida 
albicans 
krusei 
Tordopsis glabrata 
Others 
n=32 
12 (38%) 
20 (62%) 
n (25%) 
0 (0%)* 
4 (13%) 
n=25 
7 (28%) 
12 (48%) 
5 (20%) 
2 (8%) 
6 (24%)* 
13 
0 
0 
2 
n = 3 1  
19 (61%) 
2 (6%) 
16 (52%) 
10 (32%)) 
3 (1 0%) 
13 
2 
7 
7 
n=27 
14 (52%) 
2 (7?4) 
13 (48?4) 
11 (41%) 
1 (4%)) 
18 
0 
4 
8 
None of the differences were statistically significant (P>0.05), except: *P=0.005. 
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because of protocol violations. There were no 
statistically significant differences between the groups 
concerning demographic characteristics, underlying 
disea5e (Table l) ,  or predisposing factors (central 
catheters, parenteral nutrition and antibiotics, data 
not shown) for fungal infections. Bone marrow trans- 
plantation was performed on 15 (42%) fluconazole 
patients compared to 10 (30%) nystatin patients. 
The PMN count at  the start of the study, total 
duration of prophylaxis, number of days of prophylaxis 
before the appearance of neutropenia with less than 500 
PMN/mm3, total duration of neutropenia and number 
of days of extreme neutropenia with less than 100 
PMN/mm3 were not different between the two groups 
(Table 1). However the proportion of patients with a 
neutropenia of less than 100 PMN/mm3 during the 
study was slightly greater in the fluconazole than in the 
nystatin prophylaxis group (35/36 patients versus 28/33 
patients, P4.08) .  
No significant difference was found regarding 
initial fungal colonization (Table 2). 
Clinical efficacy 
One patient in the nystatin group developed a rash after 
ten days of prophylaxis and all medications were 
discontinued for five days. Another patient of the 
nystatin group became unable to take oral medication 
because of severe mucositis after 14 days of prophylaxis. 
These two patients were excluded from efficacy analysis 
(Table l) ,  but their inclusion on an intent to treat 
analysis did not affect the conclusions. 
Overall, 56% of 36 evaluable patients successfully 
completed prophylaxis with fluconazole compared to 
45% of the 31 patients on nystatin who could be 
evaluated ( P 4 . 5 ) .  Failure to complete fluconazole and 
nystatin prophylaxis was due to suspected deep-seated 
fungal infections in 14 (39%)) and 11 (36%) patients 
respectively, to oropharyngeal yeast infections in 1 (3%) 
and 5 (1 6%) patients respectively and to proven invasive 
fungal infections in one patient from each group. 
The documented deep-seated fungal infections 
were: disseniinated candidiasis with multiple positive 
blood cultures for C. pseudotropicalis in a nystatin 
patient and an aggressive pulmonary Aspergillus fumi- 
gutus infection detected at autopsy in a fluconazole 
patient. 
Superficial cutaneous yeast infections occured 
in two patients of each group. All four were due to 
C. albicans and responded to topical treatment. 
Oropharyngeal yeast infections occured slightly 
less frequently in the fluconazole group (P=0.07). 
C. albicans was the fungus responsible for all oropharyn- 
geal infections except one in the nystatin group, due to 
C. tropicalis. 
The interval between the onset of neutropenia 
and the start of amphotericin B administration for 
suspected or proven fungal infections was slightly greater 
in the fluconazole than in the nystatin prophylaxis 
group (median time interval: 24 and 21 days respec- 
tively) but the difference was not statistically significant 
(P=0. 34). 
Effect on fungal colonization 
Table 2 shows the evolution of oropharyngeal and 
stool yeast colonizations, as well as the different species 
of yeast recovered. Slightly more patients of the 
fluconazole group had baseline colonization of the 
oropharynx (38% versus 28%, P=0.6). Fluconazole was 
significantly more effective than nystatin in preventing 
new yeast colonization of the oropharynx (0% versus 
24%1, P=0.005). There was also a trend (P=0.13) 
towards a higher rate of success (patients with elimi- 
nation of initial colonization plus patients remaining 
non-colonized) and a lower rate of failure (patients 
remaining colonized and patients becoming colonized) 
for the fluconazole group. 
More than 50% of patients in both groups showed 
initial stool colonization. At the end of prophylaxis 
almost all patients of both groups had yeast stool 
colonization. 
C. albicans was the most frequent species isolated 
from stools and pharynx. In both sites, 7: glabruta was 
found slightly more frequently in the fluconazole group 
than in the nystatin group (seven versus four for the 
stools and two versus none for the pharynx, PX.5) .  
C. krusei was recovered from the stools of two 
fluconazole patients. 
Tolerance and side effects 
N o  patient had to be withdrawn because of side effects 
related to the study drugs. Oral administration of 
nystatin was discontinued in one patient because of 
vomiting. Two other patients on oral nystatin had to 
be switched to intravenous fluconazole; one because 
of severe mucositis and another because of lack of 
compliance. 
Skin rash was observed in six fluconazole and three 
nystatin patients. None of these rashes were attributed 
to the prophylactic regimen. 
Thirty-seven patients (18 on fluconazole and 19 on 
nystatin) were dead by time the study was ended (June 
1993). No death was attributed to the study drugs. 
Discussion 
This study was initially designed to investigate whether 
fluconazole (100 mg per day) would be more effective 
than the standard antifungal prophylactic regimen used 
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in our institution (nystatin, 800,000 UI per day) in 
severely neutropenic patients. After the publication of 
two much larger trials (4, 5), in which a reduction in 
the use of amphotericin B could not be demonstrated, 
even at a much higher dose of fluconazole (400 
mg/day), we decided to stop the study prematurely. 
Our results show that fluconazole (100 mg/day) 
is more effective than nystatin for the prevention of 
new oropharyngeal yeast colonization (0% versus 
24%, P=0.005) in severely neutropenic patients. This 
protective effect was associated with a reduction of 
oropharyngeal candidiasis (3% versus 16%) which did 
not reach statistical significance (P=0.07). Fluconazole 
seems to be less effective in the lower digestive tract. 
As in previous studies, nearly all patients displayed 
positive yeast stool cultures at the end of the 
study (25-28). 
High doses of fluconazole (400 mg/day) have 
been shown to decrease oropharyngeal yeast coloni- 
zation (29), oropharyngeal candidiasis (5) and systemic 
yeast infections (4) when compared to placebo. 
However, a reduction in the dose of prophylactic 
fluconazole is desirable if one considers cost (400 mg 
cost about 200 Sfr, that is $175 at the prevailing rate 
of exchange), toxicity and potential drug interactions. 
Efforts have, therefore, been made to find the optimum 
dose of fluconazole in order to prevent yeast coloni- 
zation and infections in neutropenic patients. Results 
from previous studies with lower doses are not always 
easy to interpret. Fluconazole (200 mg/day) was more 
effective than oral polyenes for the prevention of 
oropharyngeal candidiasis (30, 31). However, in one 
of these studies not all the patients were neutro- 
penic (30). Fluconazole (150 mg/day) was not more 
effective than oral polyenes in the prevention of 
oropharyngeal candidiasis (32). Fluconazole (50 mg/ 
day) reduced thrush in less immunocompromised 
cancer patients (33). In another study comparing 
fluconazole with oral polyenes, the same low dose (50 
mg/day) failed to reduce oropharyngeal yeast coloni- 
zation while reducing oropharyngeal candidiasis (25), 
but again, not all the included patients were neutro- 
penic. 
Compared to placebo, systemic yeast infections 
were reduced in one of two studies using 400 mg/ 
day fluconazole (16% versus 3%) (4). Fluconazole (200 
mg/day) reduced fungal systemic infections compared 
with oral polyenes. However, most of these infections 
were due to Aspergillus species and only three were 
due to yeasts (31). As fluconazole has little activity 
against Aspergillus species, the results of this study are 
confusing. Studies with lower doses of fluconazole have 
used controls who were on oral polyenes, instead of 
placebo, and did not demonstrate an advantage in the 
use of fluconazole because systemic yeast infections 
were rare and occurred with similar frequencies (2% to 
4%) in the fluconazole-treated group and polyene- 
treated control group at all dosages tested (25, 30-32). 
Our study also showed only one invasive yeast infection 
in the polyene group. We conclude that the apparent 
inefficacy of lower doses of fluconazole in the pre- 
vention of systemic yeast infections may well be due to 
the protective effect of oral polyenes in the control 
groups and that there is no conclusive evidence in favor 
of high doses of fluconazole (400 mg/day) compared 
to low doses (50-100 mg/day). 
Side effects were rare in the present study and 
none were attributed to the use of fluconazole. How- 
ever, the administration of nystatin became impossible 
in three patients because of vomiting and lack of 
compliance. These findings are consistent with pre- 
vious studies which concluded that fluconazole is 
easier to administer than oral polyenes in similar 
patients (32, 34). There has been concern about the 
selection of fluco-nazole-resistant species of Candida, 
such as C. krusei (35). C. krusei colonization was a rare 
event in our population, occurring in only two 
fluconazole patients (5%). T glabruta was found slightly 
more frequently in the stools and in the pharynx of 
patients receiving fluconazole (P>0.5). Both species 
were not associated with superficial or invasive disease. 
Decreased susceptibility of C. albicans after prolonged 
use of fluconazole has been described in HIV-infected 
patients (36). This seems not to be the case in our study 
population as the only patient who developed an 
oropharyngeal yeast infection due to C. albicans, while 
receiving fluconazole prophylaxis, responded well to a 
higher dose of fluconazole (400 mglday). However, we 
did not measure susceptibilities in vitro. It is possible 
that fluconazole prophylaxis given for periods of 20 
days or more is necessary for the development of new 
resistance in species which are usually susceptible to 
fluconazole. 
Based on this study, fluconazole (100 mg per day) 
seems effective in the control of both colonization 
and infections of the oropharynx by yeasts. Whether 
100 mg/day doses of fluconazole protect severely 
neutropenic patients against systemic yeast infections 
as well as 400 mg/d remains to be proven by a large 
comparative trial. In view of the low baseline frequency 
of invasive yeast infections (-3%), the logistics of such 
a trial are daunting. To show a 50% reduction (1.5% 
incidence), more than 3000 patients would have to be 
recruited. 
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